Annette Langer-Gould to United States
This is a "connection" page, showing publications Annette Langer-Gould has written about United States.
Connection Strength
0.598
-
Rituximab for Multiple Sclerosis: Hiding in Plain Sight Neurology. 2024 01 23; 102(2):e208063.
Score: 0.125
-
Health Disparities, Inequities, and Social Determinants of Health in Multiple Sclerosis and Related Disorders in the US: A Review. JAMA Neurol. 2021 12 01; 78(12):1515-1524.
Score: 0.108
-
Reader Response: Leadership, Recognition Awards, and Publication by Men and Women in the American Academy of Neurology. Neurology. 2021 07 27; 97(4):200-201.
Score: 0.106
-
Race, ethnicity, and cognition in persons newly diagnosed with multiple sclerosis. Neurology. 2020 04 07; 94(14):e1548-e1556.
Score: 0.096
-
The American Academy of Neurology's top five choosing wisely recommendations. Neurology. 2013 Sep 10; 81(11):1004-11.
Score: 0.059
-
Population-Based Estimates for the Prevalence of Multiple Sclerosis in the United States by Race, Ethnicity, Age, Sex, and Geographic Region. JAMA Neurol. 2023 07 01; 80(7):693-701.
Score: 0.030
-
A new way to estimate neurologic disease prevalence in the United States: Illustrated with MS. Neurology. 2019 03 05; 92(10):469-480.
Score: 0.022
-
The prevalence of MS in the United States: A population-based estimate using health claims data. Neurology. 2019 03 05; 92(10):e1029-e1040.
Score: 0.022
-
The American Academy of Neurology's top five Choosing Wisely recommendations. Neurology. 2013 Sep 10; 81(11):1022-3.
Score: 0.015
-
Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data. Perm J. 2012; 16(3):37-41.
Score: 0.014